2026-10-25
Everforth, clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
NAS100 29,709 +0.19%
S&P 7,737 +0.19%
GOLD $4,053 −0.54%
BTC $80,942 +0.17%
VIX 17.29 −1.31%
latest tape · as of 18:04 UTC
The Screen · Technology · Information Technology Services
Everforth, Inc.
EFOR · the NYSE · USD · Market cap $1.7B · 2,800 employees
Everforth, Inc.
Not yet scored43.59 USD
Price as of 23 Oct 2026Daily close, not a live quoteLast reviewed 5 days ago
Screened 2026-10-23 · the tape above runs as of 18:04 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price43.59 USD at the 23 Oct 2026 close
- Ethical screenNot yet scored
- OptionsOpen interest leans heavily to calls (put/call 0.01)
- Last reviewed23 Oct 2026 (5 days ago)
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 43.59 against the desk's fair-value range, base estimate 41.88, over the last year.
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.01, read 2026-10-27
- Ethical screen not yet scored
Price43.59 USD
Fair value41.88
Ethical score70.0/100
Our investment reviews on this name
2026-08-27Read Markup33.45+30.3% to today ✓Distribution gives way to Markup after a 59% rise in 8 weeks
2026-07-02Read Distribution21.02+107.4% to today First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The full research record, in depth, below
This name holds its markup label.
Everforth, Inc. holds its Markup at $43.59. The statistical read favours the buyers, held for 107 days.
| Phase | Markup |
| Quantitative state | The statistical read favours the buyers, held for 107 days |
| Price at the screen | $43.59 |
| Valuation | 21.13 trailing · 9.40 forward price to earnings |
| Values screen | Not scored · score 70.0 |
| Beta | 0.48 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 31.80% | Below 33% | Interest-bearing debt is just 31.8% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 22.72% | Below 49% | Money owed to the company is 22.7% of assets, under the 49% limit. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadThe Read, in Plain English
Everforth, clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 2026-10-27. It updates when the underlying figures move, and past reads are kept below.
2026-09-24
Clears
Everforth, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 32%, inside the ~33% line, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
What the Numbers Say It Is WorthThe Fair Value Range
Fair value range in USD, drawn from the 2026-10-23 screen. The gold marker is the market price at the same screen. A 2.1% margin of safety to the base estimate.
Third-party analyst targets: 6 covering, consensus Hold. The average target sits −23% from the screen price.
Reading the gap · Both our model and the Street see limited upside at this price.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-23 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words| Forward P/E | 9.4xvery cheap relative to earnings |
| Trailing P/E | 21.1xa premium valuation |
| EPS, trailing | 1.94 |
| EPS, forward | 4.36 |
| Revenue growth | -1.3%revenue is shrinking |
| Profit margin | 2.1%barely profitable |
| Return on equity | 4.6%a modest return on shareholder capital |
| FCF yield | 12.70% |
| Debt to equity | 0.83moderate, manageable leverage |
| Current ratio | 2.13comfortably covers its short-term bills |
| Beta | 0.48barely tracks the market's swings |
| Short interest, float | 0.10% |
| 52-week range | 16.90 - 54.94 |
| Market cap | $1.7B |
| Employees | 2,800 |
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeEFOR trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
2026-10-28
Markup $41.00
+0.0% Entry 15
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 63%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (6 analysts) rates it hold, with a mean price target of $30. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27
Markup $41.00
+0.0% Entry 14
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 63%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (6 analysts) rates it hold, with a mean price target of $30. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26
Markup $41.00
+0.0% Entry 13
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 63%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (6 analysts) rates it hold, with a mean price target of $30. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25
Markup $41.00
+0.0% Entry 12
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 63%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (6 analysts) rates it hold, with a mean price target of $30. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24
Markup $41.00
+0.0% Entry 11
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 63%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (6 analysts) rates it hold, with a mean price target of $30. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23
Markup $41.00
+3.7% Entry 10
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 3.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 63%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (6 analysts) rates it hold, with a mean price target of $30. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22
Markup $39.52
+0.0% Entry 9
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 63%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (6 analysts) rates it hold, with a mean price target of $30. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21
Markup $39.52
+5.4% Entry 8
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 5.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 63%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (6 analysts) rates it hold, with a mean price target of $30. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-14
Markup $37.50
+14.0% Entry 7
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 14.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 63%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (6 analysts) rates it hold, with a mean price target of $30. Since the last review it dropped out of the Tech 100.
2026-10-02
Markup $32.89
-1.7% Entry 6
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 1.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 63%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (6 analysts) rates it hold, with a mean price target of $30.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Is Everforth (EFOR) Reasonably Priced Or Are Cash Flows Stretched? Yahoo Finance · 3d ago
- SSi Falls 32% in Three Months: Should You Buy the Dip or Wait? Yahoo Finance · 5d ago
- Everforth, Inc. Schedules Third Quarter 2026 Earnings Release and Conference Call Yahoo Finance · 14d ago
- 3 Cash-Producing Stocks with Warning Signs Yahoo Finance · 16d ago
- Does Everforth (EFOR) Embedding Screening in Workday Deepen Its Consulting-Led Platform Strategy? Yahoo Finance · 17d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
GLOBGlobant S.A.
FORTYFormula Systems (1985) Ltd.
MGRTMega Fortune Company Limited
KEELKeel Infrastructure Corp.
INODInnodata Inc.
CNXCConcentrix Corporation
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $18.90 | +8.7% | · | $1,087 | +8.7% |
| 2 months | $35.32 | -41.8% | · | $582 | -41.8% |
| 3 months | $36.81 | -44.2% | · | $558 | -44.2% |
| 6 months | $47.62 | -56.9% | · | $432 | -56.9% |
| 1 year | $54.96 | -62.6% | · | $374 | -62.6% |
| 2 years | $92.37 | -77.8% | · | $223 | -77.8% |
| 3 years | $72.53 | -71.7% | · | $283 | -71.7% |
| 5 years | $101.46 | -79.8% | · | $203 | -79.8% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever EFOR does next, these words stay.
Membership
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.